MEDA BUYS PHARMACEUTICALS FROM NOVARTIS FOR $135 MILLION

Sweden's Meda AB has signed an agreement with the Swiss pharmaceutical company Novartis AG regarding the acquisition of the pharmaceuticals Cibacen and Cibadrex. Meda said the acquisition price for Cibacen and Cibadrex amounts to $135 million in total. Payment will occur on Jan. 20, 2005, but Meda will receive revenue of the products as of Jan. 1, 2005.

iWon (http://money.iwon.com/jsp/nw/nwdt_rt.jsp?cat=USMARKET&src=704&feed=dji§ion=news&news_id=dji-00005420050120&date=20050120&alias=/alias/money/cm/nw)

(http://money.iwon.com/jsp/nw/nwdt_rt.jsp?cat=USMARKET&src=704&feed=dji§ion=news&news_id=dji-00005420050120&date=20050120&alias=/alias/money/cm/nw)